While molecular biomarkers like MGMT methylation status are associated with treatment response (e.g., to temozolomide), their impact on clinical decision-making is still limited, particularly because treatment options for GBM remain constrained and survival outcomes are generally poor despite biomarker-guided treatment. The gene discussed is MGMT; the disease is glioblastoma.